Breakthrough may explain why cancer immunotherapies can backfire
UAlberta research findings on a critical molecule may also explain why autoimmune disease occurs.
By LESLEY YOUNG
Research by University of Alberta scientists into PD-1, a cell surface receptor that naturally plays a major role in de-escalating the body’s immune system, may explain why it can go haywire and cause autoimmune diseases like Type 1 diabetes.
“PD-1 has caused a lot of excitement in recent years as a target for new cancer immunotherapies—the theory being that by turning it off, the immune system is free to attack cancer cells—but there isn’t any scientific understanding of how it works,” said Colin Anderson, University of Alberta researcher and immunologist with the Alberta Diabetes and Transplant institutes.
His research team’s first study showed that PD-1’s ability to regulate the immune system, or T-cells, is set early on, in the fetal or neonatal period.
“In our study, we showed that it’s also pivotal when T-cells go through two phases of learning not to attack the body’s own healthy cells,” he added.
The first phase occurs when T-cells are created in the thymus; the second phase happens when they migrate to the body and go through a second mechanism called peripheral tolerance, explained Anderson.
The team’s most recent study showed that once T-cells are released from the thymus, but before they have completed the second learning mechanism, they are prone to causing autoimmune disease—and this is especially true if PD-1 is missing.
“We all harbour these newly made T-cells circulating around our body that have this increased ability to cause autoimmune disease, and this autoimmune potential is then turned off by PD-1 in healthy immune systems,” said Anderson.
Another recent study from his group asked a critical additional question: what exactly is PD-1 controlling in these new T-cells?
“Our data suggest that PD-1 is involved in setting the threshold level of signals needed to activate the T-cells, such that in the absence of PD-1 signals, the threshold level of signals needed for activation is lower, promoting widespread autoimmune attack,” said Anderson.
He said their findings not only open the door for investigating ways to intervene in PD-1 development early in life, but also between its two phases of learning to prevent autoimmune disease from developing.
“Our findings could also explain why there is an attack on many different organs rather than strictly just cancer cells seen in cancer patients treated with the new breakthrough cancer therapies that block the PD-1 receptor.”
“PD-1 Controls Tonic Signaling and Lymphopenia-Induced Proliferation of T Lymphocytes” was published in Frontiers in Immunology last October. The newer study, “Prior to Peripheral Tolerance, Newly Generated CD4 T Cells Maintain Dangerous Autoimmune Potential: Fas- and Perforin-Independent Autoimmunity Controlled by Programmed Death-1,” was published this past January, also in Frontiers in Immunology.